199 related articles for article (PubMed ID: 10607689)
1. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.
Przepiorka D; Kernan NA; Ippoliti C; Papadopoulos EB; Giralt S; Khouri I; Lu JG; Gajewski J; Durett A; Cleary K; Champlin R; Andersson BS; Light S
Blood; 2000 Jan; 95(1):83-9. PubMed ID: 10607689
[TBL] [Abstract][Full Text] [Related]
2. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.
Willenbacher W; Basara N; Blau IW; Fauser AA; Kiehl MG
Br J Haematol; 2001 Mar; 112(3):820-3. PubMed ID: 11260089
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.
Anasetti C; Hansen JA; Waldmann TA; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R
Blood; 1994 Aug; 84(4):1320-7. PubMed ID: 8049447
[TBL] [Abstract][Full Text] [Related]
4. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
Lee SJ; Zahrieh D; Agura E; MacMillan ML; Maziarz RT; McCarthy PL; Ho VT; Cutler C; Alyea EP; Antin JH; Soiffer RJ
Blood; 2004 Sep; 104(5):1559-64. PubMed ID: 15138163
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody Daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report.
Shamsi TS; Irfan M; Farzana T; Ansari SH; Ahmad G; Shakoor N; Baig MI
J Pak Med Assoc; 2005 Oct; 55(10):454-5. PubMed ID: 16304857
[TBL] [Abstract][Full Text] [Related]
6. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
[TBL] [Abstract][Full Text] [Related]
7. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.
Rager A; Frey N; Goldstein SC; Reshef R; Hexner EO; Loren A; Luger SM; Perl A; Tsai D; Davis J; Vozniak M; Smith J; Stadtmauer EA; Porter DL
Bone Marrow Transplant; 2011 Mar; 46(3):430-5. PubMed ID: 20498647
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
[TBL] [Abstract][Full Text] [Related]
13. Selective immunosuppression with daclizumab in liver transplantation with graft-versus-host disease.
Riñón M; Maruri N; Arrieta A; Fernández JR; Ortiz de Urbina J; García Masdevall MD
Transplant Proc; 2002 Feb; 34(1):109-10. PubMed ID: 11959211
[No Abstract] [Full Text] [Related]
14. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies.
Kircher B; Lätzer K; Gastl G; Nachbaur D
Clin Exp Immunol; 2003 Dec; 134(3):426-30. PubMed ID: 14632747
[TBL] [Abstract][Full Text] [Related]
16. New immunosuppressants in BMT/GVHD.
Basara N; Günzelmann S; Willenbacher W; Fauser AA; Kiehl MG
Transplant Proc; 2001 May; 33(3):2220-2. PubMed ID: 11377507
[No Abstract] [Full Text] [Related]
17. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
[No Abstract] [Full Text] [Related]
19. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
Front Immunol; 2021; 12():749266. PubMed ID: 34621279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
